financetom
Business
financetom
/
Business
/
Groupon Q3 revenue slightly beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Groupon Q3 revenue slightly beats estimates
Nov 6, 2025 2:00 PM

Overview

* Groupon ( GRPN ) Q3 global revenue up 7%, slightly beating analyst expectations

* Adjusted EBITDA for Q3 beats estimates, reflecting improved operational performance

* Company reports net loss of $117.8 mln from continuing operations

Outlook

* Company did not provide specific guidance in the press release in the statement

Result Drivers

* NORTH AMERICA GROWTH - North America Local revenue up 12% and Local billings up 18%, driving overall revenue growth

* CUSTOMER ACQUISITION - Nearly 300,000 net new active customers added, boosting sales

* INTERNATIONAL DECLINE - International revenue down 3% due to Giftcloud divestiture, but underlying growth excluding this

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $122.80 $122 mln

Global Beat* mln (3

Revenue Analysts

)

Q3 Beat $17.50 $15.30

Adjusted mln mln (2

EBITDA Analysts

)

Q3 $416.10

Billings mln

Q3 Gross $111.80

Profit mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the discount stores peer group is "buy"

* Wall Street's median 12-month price target for Groupon Inc ( GRPN ) is $34.00, about 39.8% above its November 5 closing price of $20.47

* The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 54 three months ago

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Midday Decliners
Top Midday Decliners
May 20, 2024
02:19 PM EDT, 05/20/2024 (MT Newswires) -- Virios Therapeutics ( VIRI ) said Sunday it priced a public offering of 8.5 million shares at $0.20 each to raise about $1.7 million. Shares plummeted 44% as intraday trading volume climbed to over 4.6 million versus a daily average of about 302,000. Jeffs' Brands ( JFBR ) said Monday it has signed...
Yum Brands Insider Sold Shares Worth $848,151, According to a Recent SEC Filing
Yum Brands Insider Sold Shares Worth $848,151, According to a Recent SEC Filing
May 20, 2024
02:21 PM EDT, 05/20/2024 (MT Newswires) -- Scott Catlett, Chief Legal & Franchise Officer, on May 17, 2024, sold 5,994 shares in Yum Brands ( YUM ) for $848,151. Following the Form 4 filing with the SEC, Catlett has control over a total of 34,889 shares of the company, with 34,889 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1041061/000112760224015970/xslF345X03/form4.xml Price: 139.63, Change:...
--Street Color: Microsoft Rolling Out Copilot+ PCs on June 18 for $999
--Street Color: Microsoft Rolling Out Copilot+ PCs on June 18 for $999
May 20, 2024
02:25 PM EDT, 05/20/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 424.41, Change: +4.20, Percent...
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
May 20, 2024
Monday, Esperion Therapeutics  and Otsuka Pharmaceutical Co Ltd announced that the primary endpoint in the Phase 3 trial in Japan for bempedoic acid for hypercholesterolemia was achieved.  The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan. Related: Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars. The Phase 3 trial was conducted in 96 patients with high LDL...
Copyright 2023-2026 - www.financetom.com All Rights Reserved